Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period

NCT01656720 is registered in ClinicalTrials.gov with Norgine as lead sponsor.

NCT NCT01656720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01656720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
Lead sponsor
Norgine
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
September 30, 2014
Enrollment
417 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

faecal incontinence